⏱ 2 min read
Background
Neurosterix is a Geneva-based biotechnology company created in April 2024 by Addex Therapeutics. It develops treatments for neuropsychiatric disorders. At its launch, it raised 65 million dollars in a Series A led by funds affiliated with Perceptive Advisors. Its lead candidate, NTX-253, targets schizophrenia.
The key points
On Wednesday 11 November 2026, Addex Therapeutics announced that Neurosterix had closed a Series B financing of 105 million dollars. The investors are described as a syndicate of life science investors, without being named, according to Fierce Biotech. Addex did not take part in this round.
The priority is the phase 2 trial of NTX-253 in schizophrenia. This oral drug acts on the brain’s M4 muscarinic receptors. It aims to reduce psychotic symptoms while avoiding some side effects of conventional treatments. Phase 1 studies are complete. The remaining funds will go to two other molecules, NTX-819 for mood and anxiety, and NTX-529.
The company also announced the arrival of executives specialised in neuropsychiatric drug development. Its CEO is Fred Callori, also a managing director at Perceptive Advisors.
Key figures
- 105 million dollars : size of the Series B, announced on 11 November 2026
- 65 million dollars : Series A raised in April 2024
- 8,5 % : Addex’s stake in Neurosterix, down from 20% in 2024
Who says what
- Tim Dyer (CEO of Addex Therapeutics): this financing endorses the allosteric approach developed by Addex.
What's next
- Launch of the phase 2 trial of NTX-253 in schizophrenia; no date has been given.
Further reading
Sources
- Fierce Biotech – Addex spinout Neurosterix raises $105M series B to fund phase 2 schizophrenia trial
- Neurosterix – Investors & Media
Let’s share Romandy’s news
We build the news together.
An idea, an opinion, a wish, a detail to add? Tell us!
